Though current immunotherapies for PLC have clearly shown to have some clinical effects, ICI-mediated antagonist antibodies reach clinical anti-tumour efficacy in a minor subset of advanced-stage HCC and CCA patients only (12, 15). This evidence concerns the gene HSPG2 and hepatocellular carcinoma.